Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY

Recruiting Observational Study
Papillary Thyroid Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
600 (estimated)
Sponsor
Istituto Auxologico Italiano · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutation…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * patients with papillary thyroid cancer * patients whose tumor tissue can be recovered for genetic analysis Exclusion Criteria: * patients who did not give consent * patients lost to follow-up * tumor samples not suitable for genetic analysis
Contacts

Marina Muzza, PhD

+390261191

m.muzza@auxologico.it

CONTACT